This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
keyboard_arrow_right

MAIN CONFERENCE DAY TWO

keyboard_arrow_leftSearch & Filter
search

MAIN CONFERENCE DAY TWO

search
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #1
Antigen to Preclinical Leads in 180 Days
  • Chun-Nan Chen, PhD - Chief Scientific Officer, Single Cell Technology, Inc.
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #2
Advances in Automated Microfluidic Capillary Electrophoresis for Rapid Analysis of Biologics
  • James White, PhD - Senior Application Scientist, PerkinElmer
8:10am - 8:15am5 mins
Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
Chairman’s Remarks
  • Daniel Chen, M.D., Ph.D. - Chief Medical Officer, IGM Biosciences
8:10am - 8:15am5 mins
Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
Chairman’s Remarks
  • Sai Reddy, PhD - Associate Professor, Department of Biosystems Science and Engineering at ETH Zurich, ETH Zurich
8:15am - 8:45am30 mins
Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
Improving Antibody Selection Pipelines with NGS
  • M. Frank Erasmus - Head of Bioinformatics, Specifica
8:15am - 8:45am30 mins
Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
Tumor in the Crossfire: Targeting PD-L1 and TGF-beta with Bintrafusp Alfa
  • James Gulley - Director, Medical Oncology Service, NCI, NIH
8:45am - 9:15am30 mins
Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
Conditionally Active Biologics (CABs) Antibodies for Combination Immunotherapy, T cell Recruiting Bispecifics and Drug Conjugates (ADCs)
  • Ana Paula Cugnetti, PhD - Principal Scientist, BioAtla LLC
8:45am - 9:15am30 mins
Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
Functional Anti-tumor Antibodies from Cancer Patients
  • Daniel Emerling, PhD - Senior Vice President, Research, Atreca, Inc
9:15am - 9:45am30 mins
Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
Defining the Light at the End of the Tunnel: Biologic Problems and Engineering Solutions in Cancer Immunotherapy
  • Daniel Chen, M.D., Ph.D. - Chief Medical Officer, IGM Biosciences
9:15am - 9:45am30 mins
Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
Deep Sequencing of Natural Antibody Repertoires for Antibody Discovery and Optimization and Elucidation of Repertoire Properties
  • Isidro Hotzel - Senior Scientist, Genentech
9:45am - 10:30am45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
    10:30am - 11:00am30 mins
    Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
    High Throughput Functional Profiling of Immune Repertoires
    • Bob Chen - Director of Engineering, Co-Founder, xCella Biosciences
    10:30am - 11:00am30 mins
    Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
    Understanding T-cell Bispecifics in the Clinic Using Biomarkers
    • Meghna Das Thakur - Senior Scientist, Oncology Biomarker Development, Genentech
    11:00am - 11:30am30 mins
    Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
    Finding Therapeutic Antibodies in Naturally-sourced Next Generation Sequencing Repositories
    • Konrad Krawczyk - Chief Scientific Officer, NaturalAntibody
    11:00am - 11:30am30 mins
    Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
    Clinical Use of Bispecific Antibodies in Treating B cell Lymphoma
    • Elizabeth Budde, MD, PhD - Assistant Professor, City of Hope
    11:30am - 12:00pm30 mins
    Track 2: Reverse Translation: Antibody Engineering, Clinical Data and Lessons from Cancer Immunotherapy
    Panel Discussion with Sessions Speakers
      11:30am - 12:00pm30 mins
      Track 1: Bioinformatics and Computational Tools for Antibody Optimization and Engineering
      Antigen Targets of Antibody Repertoires in Health and Disease Via Serum Epitope Repertoire Analysis
      • Patrick Daugherty - Chief Scientific Officer, Serimmune
      12:05pm - 12:35pm30 mins
      Scientific Briefing 1
      Improved Scoring Function to Efficiently Identify Antigen Epitopes
      • Johannes Maier, PhD - Principal Scientist, Schrodinger
      12:05pm - 12:35pm30 mins
      Scientific Briefing 2
      Discovery of Allosteric GPCR-modulating Antibodies
      • John Burg - Senior Scientist, Ligand Pharmaceuticals
      12:05pm - 12:35pm30 mins
      Scientific Briefing 3
      Integrated Solutions for Antibody Engineering and Beyond
      • Hua Tu, Ph.D. - President & CEO, LakePharma, Inc
      12:05pm - 12:35pm30 mins
      Scientific Briefing 4
      Targeting Membrane Proteins Using a Synthetic VHH library
      • Guy Hermans, Ph.D. - Chief Scientific Officer, Isogenica
      12:05pm - 12:35pm30 mins
      Scientific Briefing 5
      The Latest progress of the Harbour Mice® Platform
      • Jung Lee, Ph.D. - Vice President of Business Development, Harbour Antibodies US, Inc.
      12:35pm - 1:45pm70 mins
      Networking Luncheon, Exhibit and Poster Viewing
        1:45pm - 2:15pm30 mins
        Scientific Briefing 1
        Synthetic DNA Technologies Enable Single Domain Antibody Discovery
        • Aaron Sato, PhD - Chief Scientific Officer, Twist Bioscience
        1:45pm - 2:15pm30 mins
        Scientific Briefing 3
        Harnessing Picodroplet Technology to Accelerate Antibody Discovery
        • Jared Tur, Ph.D. - Senior Field Application Scientist, Sphere Fluidics
        1:45pm - 2:15pm30 mins
        Scientific Briefing 4
        From Antibody Engineering all the way to Production: High End Solutions to Expedite your Workflow
        • Bowu Luan, Ph.D. - Product Manager, GenScript USA Inc.
        • Marinella Sandros - Senior Product Manager, GenScript
        1:45pm - 2:15pm30 mins
        Scientific Briefing 5
        Systematic Technology Transfer in CRO and CMO
        • Sampath Srisailam - Associate Research Director, Syngene International Limited
        1:45pm - 2:15pm30 mins
        Scientific Briefing 2
        Developability Assessment and Property Prediction by pH-Dependent Conformational Sampling
        • Nels Thorsteinson - Scientific Services Manager, Biologics, Chemical Computing Group
        2:20pm - 2:25pm5 mins
        Track 1: Emerging Technologies and Approaches for Antibody Engineering
        Chairwoman’s Remarks
        • Jennifer Cochran, Ph.D. - Professor and Department Chair of Bioengineering, Stanford University
        2:20pm - 2:25pm5 mins
        Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
        Co-Chairs’ Remarks
        • Anne Messer, PhD - Principal Investigator, Neural Stem Cell Institute
        • James Huston, Ph.D. - Chairman, The Antibody Society , Huston BioConsulting, LLC
        2:25pm - 2:55pm30 mins
        Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
        Progress and Challenges Towards Developing Immunotherapeutics for Neurodegenerative Disorders of the Aging Population
        • Eliezer Masliah, M.D. - Director, Division of Neurosciences, National Institutes of Aging, NIH
        2:25pm - 2:55pm30 mins
        Track 1: Emerging Technologies and Approaches for Antibody Engineering
        Deep Learning Enables Therapeutic Antibody Optimization in Mammalian Cells
        • Sai Reddy, PhD - Associate Professor, Department of Biosystems Science and Engineering at ETH Zurich, ETH Zurich
        2:55pm - 3:25pm30 mins
        Track 1: Emerging Technologies and Approaches for Antibody Engineering
        Discovery of Therapeutic Functional mAbs Targeting GPCR with a Unique Single Cell Analysis Technique
        • Kiyoshi Takayama - Founder and President, NB Health Laboratory Co., Ltd.
        2:55pm - 3:30pm35 mins
        Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
        ScFv Reagents to Detect Morphology Specific Protein Variants as Biomarkers for Neurodegenerative Diseases
        • Michael Sierks - Professor, Chemical Engineering, Department of Chemical Engineering, Arizona State University
        3:25pm - 3:55pm30 mins
        Track 1: Emerging Technologies and Approaches for Antibody Engineering
        Continuous Enzyme and Antibody Evolution with OrthoRep
        • Chang Liu - Assistant Professor, University of California at Irvine
        3:30pm - 4:05pm35 mins
        Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
        Engineering of a Brain Shuttle Moiety to Increase Brain Penetration of Therapeutic Antibodies
        • Alain Tissot - Program Manager, Large Molecules, Roche Diagnostics GmbH
        3:55pm - 4:05pm10 mins
        Track 1: Emerging Technologies and Approaches for Antibody Engineering
        Short Oral Poster Presentation by Graduate Student Poster Competition Winner: RIP-Off: An Intrabody-based Strategy to Neutralize Ricin and other Ribosome-Inactivating Protein (RIP) Toxins
        • Timothy Czajka - Graduate Student, University at Albany/Wadsworth Center
        4:05pm - 4:45pm40 mins
        Networking Refreshment Break, Exhibit and Poster Viewing
          4:45pm - 5:15pm30 mins
          Track 1: Emerging Technologies and Approaches for Antibody Engineering
          Single-cell RNA Sequencing Enables Dissection of High-affinity, Allergen-specific Antibodies
          • Derek Croote, PhD - Graduate Student, Bioengineering, Stanford University
          4:45pm - 5:15pm30 mins
          Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
          Targeting RAN Proteins in C9orf72 ALS/FTD BAC Transgenic Mice
          • Laura Ranum, Ph.D. - Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics, University of Florida
          5:15pm - 5:45pm30 mins
          Track 1: Emerging Technologies and Approaches for Antibody Engineering
          Functional Screening of the B-cell Repertoire and Rapid Production of mAb Using Cell Fusion
          • Vu Truong, Ph.D. - Founder, Chief Executive Officer and Director, Aridis Pharmaceuticals
          5:15pm - 5:45pm30 mins
          Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
          Intra-neuronal Antibody Immunity to Target TDP-43 Proteinopathy
          • Jean-Pierre Julien - Professor Department of Psychiatry and Neuroscience, Laval University
          5:45pm - 6:15pm30 mins
          Track 1: Emerging Technologies and Approaches for Antibody Engineering
          Optimization of Common Light Chain Bispecific Antibodies
          • Rachel Rennard - Associate Director of In Vitro Discovery, Compass Therapeutics
          5:45pm - 6:15pm30 mins
          Track 2: Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases
          Tau Antibodies to Target Tau in Alzheimer’s Disease: From Proof of Concept to Translational Strategies
          • Cristina d'Abramo, Ph.D. - Assistant Investigator, The Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research, North Shore - LIJ
          6:15pm - 7:15pm60 mins
          Networking Reception, Exhibit and Poster Viewing
            MAIN CONFERENCE DAY ONE
            NextMAIN CONFERENCE DAY THREE

            Get the latest news.
            As it happens

            Sign up to get the latest on the agenda and speakers.
            Filter
            Streams
            Formats
            Choose Day